安进（AMGN）今日盘中股价大幅下挫，跌幅达5.64%，引起了市场的广泛关注。
消息面上，尽管公司公布的2026年第一季度财报表现强劲，调整后每股收益和营收均超出市场预期，但多重利空因素叠加导致股价承压。美国食品药品监督管理局（FDA）提议撤销对公司自身免疫性疾病药物Tavneos的批准，对其有效性及原始申请数据表示担忧，带来了重大的监管不确定性。同时，核心产品骨质疏松药物Prolia因专利到期及竞争加剧，销售额出现显著下滑。此外，公司还披露了与美国国税局（IRS）相关的潜在税务风险。这些负面消息盖过了财报的积极表现，成为股价下跌的主要原因。
值得注意的是，在股价波动之际，有分析师将安进的目标价进行了小幅上调。然而，市场情绪显然更关注于公司面临的监管挑战和核心产品销售压力，导致股价在盘中出现大幅下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.